Literature DB >> 12759289

Long term outcome of catastrophic antiphospholipid syndrome survivors.

D Erkan1, R A Asherson, G Espinosa, R Cervera, J Font, J-C Piette, M D Lockshin.   

Abstract

BACKGROUND: Catastrophic antiphospholipid syndrome (APS) is defined as life threatening multiple organ thromboses developing simultaneously or over a short period. The survival rate of catastrophic APS is about 50%, but the long term outcome of patients who survive is unknown.
OBJECTIVE: To determine the long term outcome of patients with catastrophic APS and provide further information on patients who survived. PATIENTS AND METHODS: The clinical characteristics and outcomes of 130 patients with catastrophic APS have been reported previously. Six new cases were recently added to this series. Based on these publications, the authors who reported patients who had survived were contacted. Each author was asked (a) what treatment they gave their patients after the catastrophic APS; (b) if their patients had any further thrombosis.
RESULTS: 63/136 (46%) patients died at the initial event. Of the remaining 73 patients, information was available for 58 (79%). Thirty eight (66%) patients did not develop further APS related events during an average follow up of 67.2 months. Eleven (19%) patients developed further APS related events but were still alive. No patients developed further catastrophic APS. Nine (16%) patients died: due to multiple organ failure (three patients); myelofibrosis (one); pneumonia (one); and APS related events (four).
CONCLUSION: Sixty six per cent of patients who survive an initial catastrophic APS event remained symptom free with anticoagulation during an average follow up of 67.2 months. Twenty six per cent of the survivors developed further APS related events and the mortality rate of these patients was about 25%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759289      PMCID: PMC1754574          DOI: 10.1136/ard.62.6.530

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

Review 1.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

2.  A "primary" antiphospholipid syndrome?

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1988-12       Impact factor: 4.666

Review 3.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

4.  Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.

Authors:  F J Muñoz-Rodriguez; J Font; R Cervera; J C Reverter; D Tàssies; G Espinosa; A López-Soto; F Carmona; J Balasch; A Ordinas; M Ingelmo
Journal:  Semin Arthritis Rheum       Date:  1999-12       Impact factor: 5.532

5.  Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.

Authors:  Ronald A Asherson; Gerard Espinosa; Ricard Cervera; Josep Font; Joan Carles Reverter
Journal:  J Clin Rheumatol       Date:  2002-06       Impact factor: 3.517

6.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

7.  A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.

Authors:  S Krnic-Barrie; C R O'Connor; S W Looney; S S Pierangeli; E N Harris
Journal:  Arch Intern Med       Date:  1997-10-13

8.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

9.  Primary antiphospholipid syndrome: functional outcome after 10 years.

Authors:  D Erkan; Y Yazici; R Sobel; M D Lockshin
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

10.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

View more
  21 in total

Review 1.  Catastrophic antiphospholipid syndrome.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems.

Authors:  Ljudmila Stojanovich
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  CAPS: a rare acute abdomen.

Authors:  John-Paul Smith; Mark Woodward; Oliver Tunstall; Athimalaipet Ramanan
Journal:  BMJ Case Rep       Date:  2013-07-31

4.  An extraordinary case of recurrent stroke, disseminated thrombosis and endocarditis.

Authors:  Liza Mariam Thomas; Niaz Ahmed Shaikh; Ranjana Pradeep
Journal:  BMJ Case Rep       Date:  2018-06-04

Review 5.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

Review 6.  Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome.

Authors:  Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

7.  [Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke].

Authors:  N Van Beek; N Schumacher; O Haase; D Zillikens; B Kahle; E Schmidt
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

8.  Catastrophic antiphospholipid syndrome: first signs in the neonatal period.

Authors:  Marta Cabral; Clara Abadesso; Marta Conde; Helena Almeida; Helena Carreiro
Journal:  Eur J Pediatr       Date:  2011-08-16       Impact factor: 3.183

Review 9.  Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Authors:  Silvia Bucciarelli; Doruk Erkan; Gerard Espinosa; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

10.  The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome.

Authors:  W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; G Espinosa; S Bucciarelli
Journal:  Clin Rheumatol       Date:  2007-05-24       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.